# Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia

> **NCT07258043** · — · RECRUITING · sponsor: **Hospital General de Mexico** · enrollment: 45 (estimated)

## Conditions studied

- Acute Lymphobkastic Leukemia
- Leukemia
- Overall Survival

## Interventions

- **DRUG:** Patients meeting criteria will receive DA-EPOCH via central line for 5 days every 21 days, with monitoring, supportive care, transfusions, prophylaxis, and G-CSF for 5 doses per cycle

## Key facts

- **NCT ID:** NCT07258043
- **Lead sponsor:** Hospital General de Mexico
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-23
- **Primary completion:** 2026-07-23
- **Final completion:** 2026-07-26
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07258043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07258043, "Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07258043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*